山东科学 ›› 2025, Vol. 38 ›› Issue (1): 32-43.doi: 10.3976/j.issn.1002-4026.20240052

• 药理与毒理 • 上一篇    下一篇

基于网络药理学和实验验证探讨槲皮素通过p53信号通路抗结直肠癌的作用机制

韩惠杰a(), 刘辉a, 赵永波b, 王松坡a,*()   

  1. 上海市第一人民医院 a.中医科; b.神经内科,上海 200080
  • 收稿日期:2024-04-04 出版日期:2025-02-20 发布日期:2025-01-21
  • 通信作者: 王松坡(1971—),男,主任医师,硕士生导师,研究方向为中西医结合治疗消化道疾病及肿瘤。E-mail:13386259791@163.com
  • 作者简介:韩惠杰(1981—),男,主治医师,研究方向为中西医结合诊治消化道肿瘤。E-mail:hanhuijie601@163.com
  • 基金资助:
    上海申康医院发展中心临床三年行动计划资助项目(SHDC2020CR4049);上海市进一步加快中医药事业发展三年行动计划(2021LPTD-010);第五批全国中医临床优秀人才研修项目资助(国中医药人教函〔2022〕1号)

A study based on network pharmacology and experimental verification exploring the mechanism of quercetin against colorectal cancer through the p53 signaling pathway

HAN Huijiea(), LIU Huia, ZHAO Yongbob, WANG Songpoa,*()   

  1. a. Department of TCM; b.Department of Neurology, Shanghai General Hospital, Shanghai 200080, China
  • Received:2024-04-04 Online:2025-02-20 Published:2025-01-21

摘要:

基于网络药理学、分子对接和体外实验探讨槲皮素通过p53信号通路抗结直肠癌的分子作用机制。借助TCMSP和GeneCards数据库分别获取槲皮素的药物靶点和结直肠癌的疾病靶点,并通过Venn图映射出药物靶点与疾病靶点的共同靶点;借助String数据库及Cytoscape_v3.7.2软件构建PPI网络图,同时进行GO和KEGG富集分析、分子对接及核心靶点的表达量及生存分析;最后通过细胞实验检测细胞的增殖活性、细胞凋亡水平和细胞周期阻滞变化、用药前后核心靶点及p53通路关键蛋白的表达变化。网络药理学结果提示AKT1、TP53为槲皮素抗结直肠癌的核心靶点;GO和KEGG分析筛选出槲皮素主要参与PI3K/Akt、p53信号通路;分子对接表明槲皮素与核心靶点AKT1、TP53具有较强的结合活性,TP53既在结直肠癌组织中高表达,又可影响结肠癌患者的生存预后;细胞实验结果表明槲皮素能抑制HCT-116细胞的增殖,诱导HCT-116细胞发生G0/G1期阻滞,促进细胞凋亡。该机制可能调控TP53、AKT1等核心靶点,激活p53信号通路,参与HCT-116细胞的增殖与凋亡,进而起到抗结直肠癌的作用。

关键词: 槲皮素, 结直肠癌, 网络药理学, 分子对接

Abstract:

Based on network pharmacology, molecular docking, and in vitro experiments, this study explores the molecular mechanism of quercetin against colorectal cancer through the p53 signaling pathway. The drug targets quercetin, and the disease targets colorectal cancer, which was obtained via the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform and Gene Cards database, respectively. The common drug and disease targets were mapped using a Venn diagram, and the protein-protein interaction network map was constructed with the help of the String database and Cytoscape_v3.7.2 software. At the same time, GO and KEGG enrichment analysis, molecular docking, core target expression, and survival analysis were also performed. Finally, cell proliferation activity, level of apoptosis, cell cycle arrest, and changes in the expression of core targets and key proteins of the p53 pathway were detected through cellular experiments. Network pharmacology suggests that AKT1 and TP53 are the core targets of quercetin against colorectal cancer, GO and KEGG analysis demonstrate that quercetin is mainly involved in the PI3K/Akt and p53 signaling pathways, molecular docking demonstrates that quercetin exhibits strong binding activity with the core targets AKT1 and TP53, and TP53 is found to be both highly expressed in colorectal cancerand also affect the survival and prognosis of patients with colorectal cancer. The results of cellular experiments show that quercetin can inhibit the proliferation of HCT-116 cells, induce G0/G1 cell-cycle arrest in HCT-116 cells, and promote apoptosis. This mechanism may regulate core targets such as TP53 and AKT1, activate the p53 signaling pathway, participate in the proliferation and apoptosis of HCT-116 cells, and thus function to resist colorectal cancer.

Key words: quercetin, colorectal cancer, network pharmacology, molecular docking

中图分类号: 

  • R288

开放获取 本文遵循知识共享-署名-非商业性4.0国际许可协议(CC BY-NC 4.0),允许第三方对本刊发表的论文自由共享(即在任何媒介以任何形式复制、发行原文)、演绎(即修改、转换或以原文为基础进行创作),必须给出适当的署名,提供指向本文许可协议的链接,同时表明是否对原文作了修改,不得将本文用于商业目的。CC BY-NC 4.0许可协议详情请访问 https://creativecommons.org/licenses/by-nc/4.0